Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Rises By 102.3%

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 44,712 shares, an increase of 102.3% from the June 15th total of 22,107 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 25,828 shares, the short-interest ratio is presently 1.7 days.

Barinthus Biotherapeutics Price Performance

BRNS traded up $0.01 on Wednesday, reaching $0.63. 1,898 shares of the stock were exchanged, compared to its average volume of 56,341. The company’s 50-day moving average price is $0.67 and its 200 day moving average price is $0.66. The firm has a market capitalization of $25.57 million, a PE ratio of -0.49 and a beta of -0.41. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its earnings results on Thursday, April 30th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rangeley Capital LLC raised its stake in shares of Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after buying an additional 75,024 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Barinthus Biotherapeutics by 115.8% in the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after acquiring an additional 76,800 shares during the period. Finally, Baird Financial Group Inc. lifted its holdings in Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares during the period. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.